nodes	percent_of_prediction	percent_of_DWPC	metapath
Zaleplon—AOX1—Methotrexate—lymphatic system cancer	0.221	0.324	CbGbCtD
Zaleplon—CYP3A5—Teniposide—lymphatic system cancer	0.115	0.168	CbGbCtD
Zaleplon—CYP3A7—Vincristine—lymphatic system cancer	0.0737	0.108	CbGbCtD
Zaleplon—CYP3A7-CYP3A51P—Vincristine—lymphatic system cancer	0.0737	0.108	CbGbCtD
Zaleplon—CYP3A5—Vincristine—lymphatic system cancer	0.0553	0.0811	CbGbCtD
Zaleplon—CYP3A4—Cytarabine—lymphatic system cancer	0.0454	0.0667	CbGbCtD
Zaleplon—CYP3A4—Teniposide—lymphatic system cancer	0.0448	0.0657	CbGbCtD
Zaleplon—CYP3A4—Mitoxantrone—lymphatic system cancer	0.0313	0.0459	CbGbCtD
Zaleplon—CYP3A4—Vincristine—lymphatic system cancer	0.0215	0.0316	CbGbCtD
Zaleplon—Musculoskeletal discomfort—Fludarabine—lymphatic system cancer	0.000599	0.00188	CcSEcCtD
Zaleplon—Stomatitis—Mitoxantrone—lymphatic system cancer	0.000598	0.00188	CcSEcCtD
Zaleplon—Conjunctivitis—Mitoxantrone—lymphatic system cancer	0.000596	0.00187	CcSEcCtD
Zaleplon—Urticaria—Teniposide—lymphatic system cancer	0.000594	0.00187	CcSEcCtD
Zaleplon—Glossitis—Methotrexate—lymphatic system cancer	0.000593	0.00186	CcSEcCtD
Zaleplon—Body temperature increased—Teniposide—lymphatic system cancer	0.000591	0.00186	CcSEcCtD
Zaleplon—Abdominal pain—Teniposide—lymphatic system cancer	0.000591	0.00186	CcSEcCtD
Zaleplon—Paraesthesia—Fludarabine—lymphatic system cancer	0.00059	0.00185	CcSEcCtD
Zaleplon—Hypoaesthesia—Carmustine—lymphatic system cancer	0.000589	0.00185	CcSEcCtD
Zaleplon—Hallucination—Carmustine—lymphatic system cancer	0.000589	0.00185	CcSEcCtD
Zaleplon—Hyperuricaemia—Methotrexate—lymphatic system cancer	0.000589	0.00185	CcSEcCtD
Zaleplon—Sweating—Mitoxantrone—lymphatic system cancer	0.000588	0.00185	CcSEcCtD
Zaleplon—Dyspnoea—Fludarabine—lymphatic system cancer	0.000586	0.00184	CcSEcCtD
Zaleplon—Haematuria—Mitoxantrone—lymphatic system cancer	0.000585	0.00184	CcSEcCtD
Zaleplon—Oedema peripheral—Carmustine—lymphatic system cancer	0.000583	0.00183	CcSEcCtD
Zaleplon—Dyspepsia—Fludarabine—lymphatic system cancer	0.000579	0.00182	CcSEcCtD
Zaleplon—Dysarthria—Methotrexate—lymphatic system cancer	0.000577	0.00181	CcSEcCtD
Zaleplon—Decreased appetite—Fludarabine—lymphatic system cancer	0.000571	0.00179	CcSEcCtD
Zaleplon—Visual impairment—Carmustine—lymphatic system cancer	0.000571	0.00179	CcSEcCtD
Zaleplon—Gastrointestinal disorder—Fludarabine—lymphatic system cancer	0.000567	0.00178	CcSEcCtD
Zaleplon—Hallucination—Vincristine—lymphatic system cancer	0.000562	0.00177	CcSEcCtD
Zaleplon—Hypoaesthesia—Vincristine—lymphatic system cancer	0.000562	0.00177	CcSEcCtD
Zaleplon—Constipation—Fludarabine—lymphatic system cancer	0.000562	0.00177	CcSEcCtD
Zaleplon—Pain—Fludarabine—lymphatic system cancer	0.000562	0.00177	CcSEcCtD
Zaleplon—Blood uric acid increased—Methotrexate—lymphatic system cancer	0.000556	0.00175	CcSEcCtD
Zaleplon—Eye disorder—Carmustine—lymphatic system cancer	0.000553	0.00174	CcSEcCtD
Zaleplon—Ill-defined disorder—Bleomycin—lymphatic system cancer	0.000548	0.00172	CcSEcCtD
Zaleplon—Vaginal inflammation—Methotrexate—lymphatic system cancer	0.000546	0.00172	CcSEcCtD
Zaleplon—Pulmonary embolism—Methotrexate—lymphatic system cancer	0.000546	0.00172	CcSEcCtD
Zaleplon—Anaemia—Bleomycin—lymphatic system cancer	0.000546	0.00171	CcSEcCtD
Zaleplon—Feeling abnormal—Fludarabine—lymphatic system cancer	0.000542	0.0017	CcSEcCtD
Zaleplon—Asthenia—Teniposide—lymphatic system cancer	0.000537	0.00169	CcSEcCtD
Zaleplon—Cystitis noninfective—Methotrexate—lymphatic system cancer	0.000533	0.00168	CcSEcCtD
Zaleplon—Melaena—Methotrexate—lymphatic system cancer	0.000533	0.00168	CcSEcCtD
Zaleplon—Malaise—Bleomycin—lymphatic system cancer	0.000532	0.00167	CcSEcCtD
Zaleplon—Pruritus—Teniposide—lymphatic system cancer	0.000529	0.00166	CcSEcCtD
Zaleplon—Depressed level of consciousness—Methotrexate—lymphatic system cancer	0.000527	0.00166	CcSEcCtD
Zaleplon—Cystitis—Methotrexate—lymphatic system cancer	0.000527	0.00166	CcSEcCtD
Zaleplon—Alopecia—Carmustine—lymphatic system cancer	0.000523	0.00164	CcSEcCtD
Zaleplon—Body temperature increased—Fludarabine—lymphatic system cancer	0.00052	0.00163	CcSEcCtD
Zaleplon—Mental disorder—Carmustine—lymphatic system cancer	0.000519	0.00163	CcSEcCtD
Zaleplon—Vaginal infection—Methotrexate—lymphatic system cancer	0.000516	0.00162	CcSEcCtD
Zaleplon—Malnutrition—Carmustine—lymphatic system cancer	0.000515	0.00162	CcSEcCtD
Zaleplon—Chest pain—Bleomycin—lymphatic system cancer	0.000503	0.00158	CcSEcCtD
Zaleplon—Myalgia—Bleomycin—lymphatic system cancer	0.000503	0.00158	CcSEcCtD
Zaleplon—Alopecia—Vincristine—lymphatic system cancer	0.000499	0.00157	CcSEcCtD
Zaleplon—Back pain—Carmustine—lymphatic system cancer	0.000499	0.00157	CcSEcCtD
Zaleplon—Discomfort—Bleomycin—lymphatic system cancer	0.000497	0.00156	CcSEcCtD
Zaleplon—Mental disorder—Vincristine—lymphatic system cancer	0.000495	0.00156	CcSEcCtD
Zaleplon—Chills—Mitoxantrone—lymphatic system cancer	0.000494	0.00155	CcSEcCtD
Zaleplon—Mouth ulceration—Methotrexate—lymphatic system cancer	0.000494	0.00155	CcSEcCtD
Zaleplon—Bladder pain—Methotrexate—lymphatic system cancer	0.000494	0.00155	CcSEcCtD
Zaleplon—Ecchymosis—Methotrexate—lymphatic system cancer	0.000494	0.00155	CcSEcCtD
Zaleplon—Alopecia—Mitoxantrone—lymphatic system cancer	0.000486	0.00153	CcSEcCtD
Zaleplon—Confusional state—Bleomycin—lymphatic system cancer	0.000486	0.00153	CcSEcCtD
Zaleplon—Tremor—Carmustine—lymphatic system cancer	0.000483	0.00152	CcSEcCtD
Zaleplon—Anaphylactic shock—Bleomycin—lymphatic system cancer	0.000482	0.00151	CcSEcCtD
Zaleplon—Oedema—Bleomycin—lymphatic system cancer	0.000482	0.00151	CcSEcCtD
Zaleplon—Anaemia—Carmustine—lymphatic system cancer	0.000476	0.0015	CcSEcCtD
Zaleplon—Back pain—Vincristine—lymphatic system cancer	0.000476	0.00149	CcSEcCtD
Zaleplon—Agitation—Carmustine—lymphatic system cancer	0.000474	0.00149	CcSEcCtD
Zaleplon—Asthenia—Fludarabine—lymphatic system cancer	0.000472	0.00148	CcSEcCtD
Zaleplon—Rash—Teniposide—lymphatic system cancer	0.000471	0.00148	CcSEcCtD
Zaleplon—Dermatitis—Teniposide—lymphatic system cancer	0.000471	0.00148	CcSEcCtD
Zaleplon—Dysgeusia—Mitoxantrone—lymphatic system cancer	0.000469	0.00147	CcSEcCtD
Zaleplon—Headache—Teniposide—lymphatic system cancer	0.000468	0.00147	CcSEcCtD
Zaleplon—Pruritus—Fludarabine—lymphatic system cancer	0.000465	0.00146	CcSEcCtD
Zaleplon—Lymphadenopathy—Methotrexate—lymphatic system cancer	0.000465	0.00146	CcSEcCtD
Zaleplon—Back pain—Mitoxantrone—lymphatic system cancer	0.000463	0.00146	CcSEcCtD
Zaleplon—Anorexia—Bleomycin—lymphatic system cancer	0.000459	0.00144	CcSEcCtD
Zaleplon—Thrombophlebitis—Methotrexate—lymphatic system cancer	0.000458	0.00144	CcSEcCtD
Zaleplon—Diabetes mellitus—Methotrexate—lymphatic system cancer	0.000456	0.00143	CcSEcCtD
Zaleplon—Anaemia—Vincristine—lymphatic system cancer	0.000455	0.00143	CcSEcCtD
Zaleplon—Agitation—Vincristine—lymphatic system cancer	0.000452	0.00142	CcSEcCtD
Zaleplon—Photosensitivity—Methotrexate—lymphatic system cancer	0.000451	0.00142	CcSEcCtD
Zaleplon—Hypotension—Bleomycin—lymphatic system cancer	0.00045	0.00141	CcSEcCtD
Zaleplon—Hypertension—Carmustine—lymphatic system cancer	0.000445	0.0014	CcSEcCtD
Zaleplon—Ill-defined disorder—Mitoxantrone—lymphatic system cancer	0.000445	0.0014	CcSEcCtD
Zaleplon—Nausea—Teniposide—lymphatic system cancer	0.000444	0.0014	CcSEcCtD
Zaleplon—Anaemia—Mitoxantrone—lymphatic system cancer	0.000443	0.00139	CcSEcCtD
Zaleplon—Vertigo—Vincristine—lymphatic system cancer	0.000442	0.00139	CcSEcCtD
Zaleplon—Musculoskeletal discomfort—Bleomycin—lymphatic system cancer	0.000439	0.00138	CcSEcCtD
Zaleplon—Myalgia—Carmustine—lymphatic system cancer	0.000439	0.00138	CcSEcCtD
Zaleplon—Chest pain—Carmustine—lymphatic system cancer	0.000439	0.00138	CcSEcCtD
Zaleplon—Anxiety—Carmustine—lymphatic system cancer	0.000437	0.00137	CcSEcCtD
Zaleplon—Paraesthesia—Bleomycin—lymphatic system cancer	0.000433	0.00136	CcSEcCtD
Zaleplon—Malaise—Mitoxantrone—lymphatic system cancer	0.000432	0.00136	CcSEcCtD
Zaleplon—Dyspnoea—Bleomycin—lymphatic system cancer	0.00043	0.00135	CcSEcCtD
Zaleplon—Hypertension—Vincristine—lymphatic system cancer	0.000425	0.00133	CcSEcCtD
Zaleplon—Confusional state—Carmustine—lymphatic system cancer	0.000424	0.00133	CcSEcCtD
Zaleplon—Oedema—Carmustine—lymphatic system cancer	0.000421	0.00132	CcSEcCtD
Zaleplon—Decreased appetite—Bleomycin—lymphatic system cancer	0.000419	0.00132	CcSEcCtD
Zaleplon—Myalgia—Vincristine—lymphatic system cancer	0.000419	0.00132	CcSEcCtD
Zaleplon—Rash—Fludarabine—lymphatic system cancer	0.000414	0.0013	CcSEcCtD
Zaleplon—Dermatitis—Fludarabine—lymphatic system cancer	0.000414	0.0013	CcSEcCtD
Zaleplon—Hypertension—Mitoxantrone—lymphatic system cancer	0.000414	0.0013	CcSEcCtD
Zaleplon—Pain—Bleomycin—lymphatic system cancer	0.000412	0.00129	CcSEcCtD
Zaleplon—Headache—Fludarabine—lymphatic system cancer	0.000412	0.00129	CcSEcCtD
Zaleplon—Tachycardia—Carmustine—lymphatic system cancer	0.000411	0.00129	CcSEcCtD
Zaleplon—Anaphylactoid reaction—Methotrexate—lymphatic system cancer	0.00041	0.00129	CcSEcCtD
Zaleplon—Arthralgia—Mitoxantrone—lymphatic system cancer	0.000408	0.00128	CcSEcCtD
Zaleplon—Myalgia—Mitoxantrone—lymphatic system cancer	0.000408	0.00128	CcSEcCtD
Zaleplon—Chest pain—Mitoxantrone—lymphatic system cancer	0.000408	0.00128	CcSEcCtD
Zaleplon—Anxiety—Mitoxantrone—lymphatic system cancer	0.000406	0.00128	CcSEcCtD
Zaleplon—Discomfort—Mitoxantrone—lymphatic system cancer	0.000403	0.00127	CcSEcCtD
Zaleplon—Anaphylactic shock—Vincristine—lymphatic system cancer	0.000402	0.00126	CcSEcCtD
Zaleplon—Oedema—Vincristine—lymphatic system cancer	0.000402	0.00126	CcSEcCtD
Zaleplon—Anorexia—Carmustine—lymphatic system cancer	0.000401	0.00126	CcSEcCtD
Zaleplon—Feeling abnormal—Bleomycin—lymphatic system cancer	0.000397	0.00125	CcSEcCtD
Zaleplon—Osteoarthritis—Methotrexate—lymphatic system cancer	0.000396	0.00124	CcSEcCtD
Zaleplon—Confusional state—Mitoxantrone—lymphatic system cancer	0.000394	0.00124	CcSEcCtD
Zaleplon—Nervous system disorder—Vincristine—lymphatic system cancer	0.000394	0.00124	CcSEcCtD
Zaleplon—Hypotension—Carmustine—lymphatic system cancer	0.000393	0.00123	CcSEcCtD
Zaleplon—Oedema—Mitoxantrone—lymphatic system cancer	0.000391	0.00123	CcSEcCtD
Zaleplon—Anaphylactic shock—Mitoxantrone—lymphatic system cancer	0.000391	0.00123	CcSEcCtD
Zaleplon—Nausea—Fludarabine—lymphatic system cancer	0.00039	0.00123	CcSEcCtD
Zaleplon—Hyperhidrosis—Vincristine—lymphatic system cancer	0.000388	0.00122	CcSEcCtD
Zaleplon—Shock—Mitoxantrone—lymphatic system cancer	0.000385	0.00121	CcSEcCtD
Zaleplon—Musculoskeletal discomfort—Carmustine—lymphatic system cancer	0.000383	0.0012	CcSEcCtD
Zaleplon—Urticaria—Bleomycin—lymphatic system cancer	0.000383	0.0012	CcSEcCtD
Zaleplon—Anorexia—Vincristine—lymphatic system cancer	0.000383	0.0012	CcSEcCtD
Zaleplon—Tachycardia—Mitoxantrone—lymphatic system cancer	0.000382	0.0012	CcSEcCtD
Zaleplon—Body temperature increased—Bleomycin—lymphatic system cancer	0.000381	0.0012	CcSEcCtD
Zaleplon—Insomnia—Carmustine—lymphatic system cancer	0.00038	0.00119	CcSEcCtD
Zaleplon—Skin disorder—Mitoxantrone—lymphatic system cancer	0.00038	0.00119	CcSEcCtD
Zaleplon—Irritability—Methotrexate—lymphatic system cancer	0.000378	0.00119	CcSEcCtD
Zaleplon—Hyperhidrosis—Mitoxantrone—lymphatic system cancer	0.000378	0.00119	CcSEcCtD
Zaleplon—Paraesthesia—Carmustine—lymphatic system cancer	0.000378	0.00119	CcSEcCtD
Zaleplon—Mood swings—Methotrexate—lymphatic system cancer	0.000376	0.00118	CcSEcCtD
Zaleplon—Hypotension—Vincristine—lymphatic system cancer	0.000375	0.00118	CcSEcCtD
Zaleplon—Dyspnoea—Carmustine—lymphatic system cancer	0.000375	0.00118	CcSEcCtD
Zaleplon—Somnolence—Carmustine—lymphatic system cancer	0.000374	0.00117	CcSEcCtD
Zaleplon—Anorexia—Mitoxantrone—lymphatic system cancer	0.000373	0.00117	CcSEcCtD
Zaleplon—Ataxia—Methotrexate—lymphatic system cancer	0.000373	0.00117	CcSEcCtD
Zaleplon—Liver function test abnormal—Methotrexate—lymphatic system cancer	0.000366	0.00115	CcSEcCtD
Zaleplon—Musculoskeletal discomfort—Vincristine—lymphatic system cancer	0.000366	0.00115	CcSEcCtD
Zaleplon—Decreased appetite—Carmustine—lymphatic system cancer	0.000366	0.00115	CcSEcCtD
Zaleplon—Hypotension—Mitoxantrone—lymphatic system cancer	0.000365	0.00115	CcSEcCtD
Zaleplon—Insomnia—Vincristine—lymphatic system cancer	0.000363	0.00114	CcSEcCtD
Zaleplon—Gastrointestinal disorder—Carmustine—lymphatic system cancer	0.000363	0.00114	CcSEcCtD
Zaleplon—Paraesthesia—Vincristine—lymphatic system cancer	0.000361	0.00113	CcSEcCtD
Zaleplon—Constipation—Carmustine—lymphatic system cancer	0.00036	0.00113	CcSEcCtD
Zaleplon—Pain—Carmustine—lymphatic system cancer	0.00036	0.00113	CcSEcCtD
Zaleplon—Breast disorder—Methotrexate—lymphatic system cancer	0.000358	0.00113	CcSEcCtD
Zaleplon—Musculoskeletal discomfort—Mitoxantrone—lymphatic system cancer	0.000356	0.00112	CcSEcCtD
Zaleplon—Paraesthesia—Mitoxantrone—lymphatic system cancer	0.000351	0.0011	CcSEcCtD
Zaleplon—Decreased appetite—Vincristine—lymphatic system cancer	0.000349	0.0011	CcSEcCtD
Zaleplon—Dyspnoea—Mitoxantrone—lymphatic system cancer	0.000349	0.00109	CcSEcCtD
Zaleplon—Somnolence—Mitoxantrone—lymphatic system cancer	0.000348	0.00109	CcSEcCtD
Zaleplon—Gastrointestinal disorder—Vincristine—lymphatic system cancer	0.000347	0.00109	CcSEcCtD
Zaleplon—Feeling abnormal—Carmustine—lymphatic system cancer	0.000347	0.00109	CcSEcCtD
Zaleplon—Asthenia—Bleomycin—lymphatic system cancer	0.000346	0.00109	CcSEcCtD
Zaleplon—Dyspepsia—Mitoxantrone—lymphatic system cancer	0.000344	0.00108	CcSEcCtD
Zaleplon—Gastrointestinal pain—Carmustine—lymphatic system cancer	0.000344	0.00108	CcSEcCtD
Zaleplon—Pain—Vincristine—lymphatic system cancer	0.000343	0.00108	CcSEcCtD
Zaleplon—Constipation—Vincristine—lymphatic system cancer	0.000343	0.00108	CcSEcCtD
Zaleplon—Asthma—Methotrexate—lymphatic system cancer	0.000343	0.00108	CcSEcCtD
Zaleplon—Pruritus—Bleomycin—lymphatic system cancer	0.000341	0.00107	CcSEcCtD
Zaleplon—Decreased appetite—Mitoxantrone—lymphatic system cancer	0.00034	0.00107	CcSEcCtD
Zaleplon—Eosinophilia—Methotrexate—lymphatic system cancer	0.000339	0.00107	CcSEcCtD
Zaleplon—Constipation—Mitoxantrone—lymphatic system cancer	0.000334	0.00105	CcSEcCtD
Zaleplon—Pain—Mitoxantrone—lymphatic system cancer	0.000334	0.00105	CcSEcCtD
Zaleplon—Abdominal pain—Carmustine—lymphatic system cancer	0.000332	0.00104	CcSEcCtD
Zaleplon—Body temperature increased—Carmustine—lymphatic system cancer	0.000332	0.00104	CcSEcCtD
Zaleplon—Gastrointestinal pain—Vincristine—lymphatic system cancer	0.000328	0.00103	CcSEcCtD
Zaleplon—Feeling abnormal—Mitoxantrone—lymphatic system cancer	0.000322	0.00101	CcSEcCtD
Zaleplon—Dysuria—Methotrexate—lymphatic system cancer	0.00032	0.00101	CcSEcCtD
Zaleplon—Gastrointestinal pain—Mitoxantrone—lymphatic system cancer	0.00032	0.001	CcSEcCtD
Zaleplon—Body temperature increased—Vincristine—lymphatic system cancer	0.000317	0.000997	CcSEcCtD
Zaleplon—Abdominal pain—Vincristine—lymphatic system cancer	0.000317	0.000997	CcSEcCtD
Zaleplon—Erectile dysfunction—Methotrexate—lymphatic system cancer	0.000316	0.000991	CcSEcCtD
Zaleplon—Photosensitivity reaction—Methotrexate—lymphatic system cancer	0.000313	0.000982	CcSEcCtD
Zaleplon—Urticaria—Mitoxantrone—lymphatic system cancer	0.000311	0.000976	CcSEcCtD
Zaleplon—Abdominal pain—Mitoxantrone—lymphatic system cancer	0.000309	0.000971	CcSEcCtD
Zaleplon—Body temperature increased—Mitoxantrone—lymphatic system cancer	0.000309	0.000971	CcSEcCtD
Zaleplon—Pneumonia—Methotrexate—lymphatic system cancer	0.000307	0.000965	CcSEcCtD
Zaleplon—Depression—Methotrexate—lymphatic system cancer	0.000305	0.000957	CcSEcCtD
Zaleplon—Rash—Bleomycin—lymphatic system cancer	0.000304	0.000954	CcSEcCtD
Zaleplon—Dermatitis—Bleomycin—lymphatic system cancer	0.000304	0.000953	CcSEcCtD
Zaleplon—Asthenia—Carmustine—lymphatic system cancer	0.000302	0.000948	CcSEcCtD
Zaleplon—Stomatitis—Methotrexate—lymphatic system cancer	0.000298	0.000935	CcSEcCtD
Zaleplon—Conjunctivitis—Methotrexate—lymphatic system cancer	0.000297	0.000933	CcSEcCtD
Zaleplon—Sweating—Methotrexate—lymphatic system cancer	0.000293	0.00092	CcSEcCtD
Zaleplon—Haematuria—Methotrexate—lymphatic system cancer	0.000291	0.000915	CcSEcCtD
Zaleplon—Hepatobiliary disease—Methotrexate—lymphatic system cancer	0.000289	0.000907	CcSEcCtD
Zaleplon—Epistaxis—Methotrexate—lymphatic system cancer	0.000288	0.000905	CcSEcCtD
Zaleplon—Asthenia—Vincristine—lymphatic system cancer	0.000288	0.000905	CcSEcCtD
Zaleplon—Nausea—Bleomycin—lymphatic system cancer	0.000286	0.000899	CcSEcCtD
Zaleplon—Asthenia—Mitoxantrone—lymphatic system cancer	0.000281	0.000881	CcSEcCtD
Zaleplon—Dizziness—Carmustine—lymphatic system cancer	0.000278	0.000874	CcSEcCtD
Zaleplon—Dizziness—Vincristine—lymphatic system cancer	0.000266	0.000834	CcSEcCtD
Zaleplon—Rash—Carmustine—lymphatic system cancer	0.000265	0.000833	CcSEcCtD
Zaleplon—Dermatitis—Carmustine—lymphatic system cancer	0.000265	0.000832	CcSEcCtD
Zaleplon—Visual impairment—Methotrexate—lymphatic system cancer	0.000264	0.00083	CcSEcCtD
Zaleplon—Headache—Carmustine—lymphatic system cancer	0.000263	0.000828	CcSEcCtD
Zaleplon—Eye disorder—Methotrexate—lymphatic system cancer	0.000256	0.000805	CcSEcCtD
Zaleplon—Tinnitus—Methotrexate—lymphatic system cancer	0.000256	0.000803	CcSEcCtD
Zaleplon—Rash—Vincristine—lymphatic system cancer	0.000253	0.000795	CcSEcCtD
Zaleplon—Dermatitis—Vincristine—lymphatic system cancer	0.000253	0.000794	CcSEcCtD
Zaleplon—Headache—Vincristine—lymphatic system cancer	0.000252	0.00079	CcSEcCtD
Zaleplon—Nausea—Carmustine—lymphatic system cancer	0.00025	0.000785	CcSEcCtD
Zaleplon—Immune system disorder—Methotrexate—lymphatic system cancer	0.000248	0.000778	CcSEcCtD
Zaleplon—Rash—Mitoxantrone—lymphatic system cancer	0.000247	0.000774	CcSEcCtD
Zaleplon—Dermatitis—Mitoxantrone—lymphatic system cancer	0.000246	0.000774	CcSEcCtD
Zaleplon—Chills—Methotrexate—lymphatic system cancer	0.000246	0.000773	CcSEcCtD
Zaleplon—Headache—Mitoxantrone—lymphatic system cancer	0.000245	0.000769	CcSEcCtD
Zaleplon—Alopecia—Methotrexate—lymphatic system cancer	0.000242	0.000761	CcSEcCtD
Zaleplon—Mental disorder—Methotrexate—lymphatic system cancer	0.00024	0.000755	CcSEcCtD
Zaleplon—Malnutrition—Methotrexate—lymphatic system cancer	0.000239	0.00075	CcSEcCtD
Zaleplon—Nausea—Vincristine—lymphatic system cancer	0.000238	0.000749	CcSEcCtD
Zaleplon—Dysgeusia—Methotrexate—lymphatic system cancer	0.000234	0.000734	CcSEcCtD
Zaleplon—Nausea—Mitoxantrone—lymphatic system cancer	0.000232	0.000729	CcSEcCtD
Zaleplon—Back pain—Methotrexate—lymphatic system cancer	0.000231	0.000725	CcSEcCtD
Zaleplon—Ill-defined disorder—Methotrexate—lymphatic system cancer	0.000221	0.000696	CcSEcCtD
Zaleplon—Anaemia—Methotrexate—lymphatic system cancer	0.000221	0.000693	CcSEcCtD
Zaleplon—Malaise—Methotrexate—lymphatic system cancer	0.000215	0.000676	CcSEcCtD
Zaleplon—Vertigo—Methotrexate—lymphatic system cancer	0.000214	0.000674	CcSEcCtD
Zaleplon—Myalgia—Methotrexate—lymphatic system cancer	0.000203	0.000638	CcSEcCtD
Zaleplon—Chest pain—Methotrexate—lymphatic system cancer	0.000203	0.000638	CcSEcCtD
Zaleplon—Arthralgia—Methotrexate—lymphatic system cancer	0.000203	0.000638	CcSEcCtD
Zaleplon—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—lymphatic system cancer	0.000202	0.000634	CcSEcCtD
Zaleplon—Discomfort—Methotrexate—lymphatic system cancer	0.000201	0.000631	CcSEcCtD
Zaleplon—Confusional state—Methotrexate—lymphatic system cancer	0.000196	0.000617	CcSEcCtD
Zaleplon—Anaphylactic shock—Methotrexate—lymphatic system cancer	0.000195	0.000612	CcSEcCtD
Zaleplon—Nervous system disorder—Methotrexate—lymphatic system cancer	0.000191	0.0006	CcSEcCtD
Zaleplon—Skin disorder—Methotrexate—lymphatic system cancer	0.000189	0.000594	CcSEcCtD
Zaleplon—Hyperhidrosis—Methotrexate—lymphatic system cancer	0.000188	0.000592	CcSEcCtD
Zaleplon—Anorexia—Methotrexate—lymphatic system cancer	0.000186	0.000583	CcSEcCtD
Zaleplon—Hypotension—Methotrexate—lymphatic system cancer	0.000182	0.000572	CcSEcCtD
Zaleplon—Musculoskeletal discomfort—Methotrexate—lymphatic system cancer	0.000177	0.000557	CcSEcCtD
Zaleplon—Insomnia—Methotrexate—lymphatic system cancer	0.000176	0.000553	CcSEcCtD
Zaleplon—Paraesthesia—Methotrexate—lymphatic system cancer	0.000175	0.000549	CcSEcCtD
Zaleplon—Dyspnoea—Methotrexate—lymphatic system cancer	0.000174	0.000546	CcSEcCtD
Zaleplon—Somnolence—Methotrexate—lymphatic system cancer	0.000173	0.000544	CcSEcCtD
Zaleplon—Dyspepsia—Methotrexate—lymphatic system cancer	0.000171	0.000539	CcSEcCtD
Zaleplon—Decreased appetite—Methotrexate—lymphatic system cancer	0.000169	0.000532	CcSEcCtD
Zaleplon—Gastrointestinal disorder—Methotrexate—lymphatic system cancer	0.000168	0.000528	CcSEcCtD
Zaleplon—Pain—Methotrexate—lymphatic system cancer	0.000167	0.000523	CcSEcCtD
Zaleplon—Feeling abnormal—Methotrexate—lymphatic system cancer	0.000161	0.000504	CcSEcCtD
Zaleplon—Gastrointestinal pain—Methotrexate—lymphatic system cancer	0.000159	0.0005	CcSEcCtD
Zaleplon—Urticaria—Methotrexate—lymphatic system cancer	0.000155	0.000486	CcSEcCtD
Zaleplon—Abdominal pain—Methotrexate—lymphatic system cancer	0.000154	0.000484	CcSEcCtD
Zaleplon—Body temperature increased—Methotrexate—lymphatic system cancer	0.000154	0.000484	CcSEcCtD
Zaleplon—Asthenia—Methotrexate—lymphatic system cancer	0.00014	0.000439	CcSEcCtD
Zaleplon—Pruritus—Methotrexate—lymphatic system cancer	0.000138	0.000433	CcSEcCtD
Zaleplon—Dizziness—Methotrexate—lymphatic system cancer	0.000129	0.000405	CcSEcCtD
Zaleplon—Rash—Methotrexate—lymphatic system cancer	0.000123	0.000386	CcSEcCtD
Zaleplon—Dermatitis—Methotrexate—lymphatic system cancer	0.000123	0.000385	CcSEcCtD
Zaleplon—Headache—Methotrexate—lymphatic system cancer	0.000122	0.000383	CcSEcCtD
Zaleplon—Nausea—Methotrexate—lymphatic system cancer	0.000116	0.000363	CcSEcCtD
